JP6180485B2 - オイル組成物、オイル組成物を含む製剤、及び内蔵脂肪の蓄積を減らし、ブドウ糖耐性を向上させて肥満関連疾患及び障害を予防又は治療するためのその使用 - Google Patents
オイル組成物、オイル組成物を含む製剤、及び内蔵脂肪の蓄積を減らし、ブドウ糖耐性を向上させて肥満関連疾患及び障害を予防又は治療するためのその使用 Download PDFInfo
- Publication number
- JP6180485B2 JP6180485B2 JP2015203900A JP2015203900A JP6180485B2 JP 6180485 B2 JP6180485 B2 JP 6180485B2 JP 2015203900 A JP2015203900 A JP 2015203900A JP 2015203900 A JP2015203900 A JP 2015203900A JP 6180485 B2 JP6180485 B2 JP 6180485B2
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- fat
- oil
- pharmaceutical composition
- obesity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 92
- 238000009472 formulation Methods 0.000 title claims description 9
- 208000008589 Obesity Diseases 0.000 title description 41
- 235000020824 obesity Nutrition 0.000 title description 41
- 238000009825 accumulation Methods 0.000 title description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title description 19
- 239000008103 glucose Substances 0.000 title description 19
- 208000037765 diseases and disorders Diseases 0.000 title 1
- 239000003925 fat Substances 0.000 title 1
- 239000003921 oil Substances 0.000 claims description 89
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 30
- 239000004164 Wax ester Substances 0.000 claims description 29
- 235000019386 wax ester Nutrition 0.000 claims description 29
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 22
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 19
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 19
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 19
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 19
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 18
- 241000239250 Copepoda Species 0.000 claims description 17
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 17
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 15
- 208000004611 Abdominal Obesity Diseases 0.000 claims description 14
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 claims description 13
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 claims description 13
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 229930195729 fatty acid Natural products 0.000 claims description 12
- 239000000194 fatty acid Substances 0.000 claims description 12
- 206010065941 Central obesity Diseases 0.000 claims description 11
- 150000004665 fatty acids Chemical class 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 8
- 241000239263 Calanus Species 0.000 claims description 7
- 150000002191 fatty alcohols Chemical class 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 4
- -1 C22 fatty acid Chemical class 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 3
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 3
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 235000006708 antioxidants Nutrition 0.000 claims description 3
- 235000013793 astaxanthin Nutrition 0.000 claims description 3
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 3
- 229940022405 astaxanthin Drugs 0.000 claims description 3
- 239000001168 astaxanthin Substances 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 235000019198 oils Nutrition 0.000 description 87
- 235000009200 high fat diet Nutrition 0.000 description 57
- 235000019197 fats Nutrition 0.000 description 32
- 241000700159 Rattus Species 0.000 description 24
- 235000005911 diet Nutrition 0.000 description 24
- 230000035508 accumulation Effects 0.000 description 21
- 210000001596 intra-abdominal fat Anatomy 0.000 description 20
- 230000037213 diet Effects 0.000 description 17
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 235000013305 food Nutrition 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 235000021068 Western diet Nutrition 0.000 description 10
- 235000020940 control diet Nutrition 0.000 description 10
- 235000019688 fish Nutrition 0.000 description 8
- 235000004213 low-fat Nutrition 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 241000251468 Actinopterygii Species 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 230000000378 dietary effect Effects 0.000 description 7
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 239000001993 wax Substances 0.000 description 6
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 235000021323 fish oil Nutrition 0.000 description 5
- 238000007446 glucose tolerance test Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 229940106134 krill oil Drugs 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000972773 Aulopiformes Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000006866 deterioration Effects 0.000 description 4
- 235000005686 eating Nutrition 0.000 description 4
- 230000004217 heart function Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 235000019515 salmon Nutrition 0.000 description 4
- 239000003760 tallow Substances 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 241000277331 Salmonidae Species 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 239000003026 cod liver oil Substances 0.000 description 3
- 235000012716 cod liver oil Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 230000009278 visceral effect Effects 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 241000276438 Gadus morhua Species 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 210000000579 abdominal fat Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000000593 adipose tissue white Anatomy 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000009360 aquaculture Methods 0.000 description 2
- 244000144974 aquaculture Species 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000010773 plant oil Substances 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 235000021195 test diet Nutrition 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000239266 Calanus finmarchicus Species 0.000 description 1
- 241000186240 Calanus hyperboreus Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000204888 Geobacter sp. Species 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 241000283222 Physeter catodon Species 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000010352 biotechnological method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 235000021316 daily nutritional intake Nutrition 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013229 diet-induced obese mouse Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000009372 pisciculture Methods 0.000 description 1
- 229960001109 policosanol Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000003868 tissue accumulation Effects 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
- A23D9/013—Other fatty acid esters, e.g. phosphatides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Insects & Arthropods (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Marine Sciences & Fisheries (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fodder In General (AREA)
- Medicinal Preparation (AREA)
- Fats And Perfumes (AREA)
Description
2 出典:Falch, et al., Process Biochemistry 2006;41: 666-674
3 出典:Phleger, et al. Comparative Biochemistry and Physiology Part B 2002;131:733-747
4 出典:Standal et al., J. Am Oil Chem Soc 2008; 85:105-112
5 出典:Hagen et al., Marine Biology 2001;139:95-104
動物実験は、ノルウェーのトロムソ大学医学部で行われた。6週齢ウィスターラット(平均重量162グラム)を個別に檻に入れ、21℃、湿度55%及び12:12hの明暗サイクル(午前7時から午後7時まで灯火)を維持した部屋に収容した。動物は、水と飼料が自由摂取であった。すべての手順は、ノルウェーの実験動物委員会の承認を得て、実験及び他の科学的目的に使用される脊椎動物の保護に関する欧州協定(EST NR. 123, 1986)に基づいた。ラットは、TestDiet(www.testdiet.com)によって製造された3つの異なる食餌を110日間、摂食させた:1) 4%の脂肪(2.37%のダイズ油及び1.89%のラード(w/w))を含んでいるコントロール食であり、総食餌エネルギー量の10%(コントロール(3.75kcal/g))にあたる;2) 24%の脂肪(2.89%のダイズ油及び20.68%のラード(w/w))を含んでいる、肥満症を誘導する高脂肪食であり、総食餌エネルギー量の45%(HF、4.65kcal/g)にあたる;3) 24%の脂肪(2.91%のダイズ油、19.15%のラード及び1.5%の本発明のオイル製剤)を含んでいる実験的な高脂肪食であり、総食餌エネルギー量の45%(HF + 1.5% CO、4.47kcal/g飼料)にあたる。食餌は、抗酸化剤又は防腐剤なしで調製され、摂食させる前まで凍結保存した。
表3:低脂肪対照食(コントロール)、肥満症を誘導する高脂肪食(HF)及び1.5重量%の本発明にかかるオイル製剤を含む実験的な高脂肪食(HF + 1.5% CO)を摂食させたラットに関する生物測定データ。飼養試験のスタート時の体重(胴体wt スタート)、飼養試験終了後の体重(胴体wt 屠殺)、飼養試験終了後の肝臓重量(肝臓wt)、飼養試験終了後の心臓重量(心臓wt)並びに、飼養試験終了後の心臓重量と体重との比率及び心臓重量と脛骨(けい骨)の長さ(mm)との比率に関する値。値は、平均±95% C.I.(n= 10)である。
Claims (15)
- 20-100重量%のロウエステルを含む、カイアシから単離されたオイル組成物であって、
前記ロウエステルは、一価又は多価不飽和C16からC22脂肪酸と一価不飽和C16からC22脂肪族アルコールのモノエステルからなり、
前記脂肪酸は、5-20重量%のステアリドン酸(SDA)を含む、
カイアシから単離されたオイル組成物を含む、腹部肥満症及び2型糖尿病の予防用又は治療用薬剤として使用するための医薬組成物。 - 40-85重量%のロウエステルを含む、請求項1に記載の医薬組成物。
- 前記ロウエステルにおける前記一価不飽和脂肪族アルコールの70%以上は、C16:1、C20:1及びC22:1である、請求項1又は2に記載の医薬組成物。
- 前記ロウエステルにおける前記脂肪族アルコールの70%以上は、一価不飽和であり、
前記ロウエステルにおける前記脂肪酸の50%以上は、一価又は多価不飽和n-3脂肪酸のいずれかである、請求項1又は2に記載の医薬組成物。 - 前記組成物は、3-20重量%のエイコサペンタエン酸(EPA)と2-15重量%のドコサヘキサエン酸(DHA)を含む、請求項1から4のいずれかに記載の医薬組成物。
- 前記組成物は、モノエステルとして脂肪族アルコール並びにSDA、DHA及びEPAを含む、請求項1から5のいずれかに記載の医薬組成物。
- 前記組成物は、500-4000ppmのアスタキサンチンを含む、請求項1から6のいずれかに記載の医薬組成物。
- 前記カイアシは、カラヌス属である、請求項7に記載の医薬組成物。
- 前記カイアシは、カラヌス フィンマルキクス種である、請求項8に記載の医薬組成物。
- 請求項1から9のいずれかに記載の組成物を含む、腹部肥満症及び2型糖尿病の予防用又は治療用栄養補助食品製剤。
- 請求項1から9のいずれかに記載の組成物を含む、腹部肥満症及び2型糖尿病の予防用又は治療用機能性食品又は飼料製剤。
- 請求項1から9のいずれかに記載の組成物を含む、腹部肥満症及び2型糖尿病の予防用又は治療用医薬製剤。
- カプセル、錠剤、乳化剤にて提供される、請求項10又は12に記載の製剤。
- アジュバント、安定剤、抗酸化剤、乳化剤、界面活性剤及び担体からなる群より選択される1又は複数の医薬的に許容可能な添加剤を含む、請求項13に記載の製剤。
- 腹部肥満症及び2型糖尿病の予防又は治療のための薬剤の製造に関する、請求項1から9のいずれかに記載の組成物の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO20092282 | 2009-06-12 | ||
NO20092282 | 2009-06-12 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012514911A Division JP2012529503A (ja) | 2009-06-12 | 2010-06-11 | オイル組成物、オイル組成物を含む製剤、及び内蔵脂肪の蓄積を減らし、ブドウ糖耐性を向上させて肥満関連疾患及び障害を予防又は治療するためのその使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016074665A JP2016074665A (ja) | 2016-05-12 |
JP6180485B2 true JP6180485B2 (ja) | 2017-08-16 |
Family
ID=42349680
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012514911A Pending JP2012529503A (ja) | 2009-06-12 | 2010-06-11 | オイル組成物、オイル組成物を含む製剤、及び内蔵脂肪の蓄積を減らし、ブドウ糖耐性を向上させて肥満関連疾患及び障害を予防又は治療するためのその使用 |
JP2015203900A Active JP6180485B2 (ja) | 2009-06-12 | 2015-10-15 | オイル組成物、オイル組成物を含む製剤、及び内蔵脂肪の蓄積を減らし、ブドウ糖耐性を向上させて肥満関連疾患及び障害を予防又は治療するためのその使用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012514911A Pending JP2012529503A (ja) | 2009-06-12 | 2010-06-11 | オイル組成物、オイル組成物を含む製剤、及び内蔵脂肪の蓄積を減らし、ブドウ糖耐性を向上させて肥満関連疾患及び障害を予防又は治療するためのその使用 |
Country Status (9)
Country | Link |
---|---|
US (2) | US20120136053A1 (ja) |
EP (1) | EP2440065B1 (ja) |
JP (2) | JP2012529503A (ja) |
CN (1) | CN102802428B (ja) |
CA (1) | CA2765329C (ja) |
DK (1) | DK2440065T3 (ja) |
ES (1) | ES2697533T3 (ja) |
RU (1) | RU2539921C2 (ja) |
WO (1) | WO2010143977A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201700054543A1 (it) * | 2017-05-19 | 2018-11-19 | Gleaner Srls | Preparato come fonte di Omega-3 |
CN111357979A (zh) * | 2019-12-26 | 2020-07-03 | 浙江欧谱生物科技有限公司 | 抑制高脂引起的肥胖及骨丢失的保健食品组合物及其应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1277953B1 (it) * | 1995-12-21 | 1997-11-12 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per |
IT1292126B1 (it) * | 1997-06-11 | 1999-01-25 | Guido Galliani | Esteri cerosi arricchiti in acidi grassi omega-3 insaturi,loro preparazione ed uso |
CA2251265A1 (en) | 1998-10-21 | 2000-04-21 | Universite De Sherbrooke | Process for lipid extraction of aquatic animal tissues producing a dehydrated residue |
CA2290885A1 (fr) | 1999-12-02 | 2001-06-02 | Universite De Sherbrooke | Methode pour la transformation des tissus du loup marin |
GB0016452D0 (en) * | 2000-07-04 | 2000-08-23 | Kilgowan Limited | Vitamin K and essential fatty acids |
WO2002072119A1 (en) * | 2001-03-09 | 2002-09-19 | Vladimir Vuksan | Salvia hispanica l. (chia) in the management and treatment of cardiovascular disease, diabetes and associated risk factors |
US6500468B1 (en) * | 2002-01-03 | 2002-12-31 | Farlong Pharmaceutical, Inc. | Panax notoginsenoside composition |
NZ539625A (en) * | 2002-09-27 | 2007-11-30 | Martek Biosciences Corp | Improved glycemic control for Prediabetes and/or Diabetes Type II Using Docosahexaenoic Acid |
WO2004066938A2 (en) * | 2003-01-28 | 2004-08-12 | University Of Georgia Research Foundation, Inc. | Method and composition for lowering cholesterol |
JP4152818B2 (ja) * | 2003-02-06 | 2008-09-17 | 日清オイリオグループ株式会社 | 共役脂肪酸を有効成分とする高血圧予防剤およびその用途 |
SE0303513D0 (sv) * | 2003-12-19 | 2003-12-19 | Pronova Biocare As | Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof |
US8075910B2 (en) * | 2004-05-20 | 2011-12-13 | Pbm Pharmaceuticals, Inc. | Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions |
ITRM20040395A1 (it) * | 2004-08-03 | 2004-11-03 | Sigma Tau Ind Farmaceuti | Composizione comprendente statine e acidi grassi omega 3. |
US20060088574A1 (en) * | 2004-10-25 | 2006-04-27 | Manning Paul B | Nutritional supplements |
BRPI0519642A8 (pt) | 2004-12-29 | 2017-10-03 | Hill´S Pet Nutrition Inc | Método para inibir um declínio em aprendizagem e/ou memória, kit apropriado para administrar um ou mais antioxidantes a um animal, meio para transmitir informação, e, uso de uma composição |
CA2667150A1 (en) * | 2006-11-01 | 2008-11-06 | Pronova Biopharma Norge As | Omega-3 lipid compounds |
EP2094823A4 (en) * | 2006-11-16 | 2011-02-02 | Pronova Biopharma Norge As | PROCESS FOR THE PRODUCTION OF OMEGA-3 RICH MARINE PHOSPHOLIPIDS FROM KRILL |
EP2144618B1 (en) * | 2007-03-28 | 2013-05-15 | Aker Biomarine ASA | Bioeffective krill oil compositions |
JP2012514596A (ja) * | 2009-01-05 | 2012-06-28 | カラナス エーエス | バイオオイル組成物、上記オイル組成物を含む製剤と、循環器疾患の予防又は治療のためのその使用 |
-
2010
- 2010-06-11 CA CA2765329A patent/CA2765329C/en active Active
- 2010-06-11 WO PCT/NO2010/000223 patent/WO2010143977A1/en active Application Filing
- 2010-06-11 CN CN201080025385.7A patent/CN102802428B/zh active Active
- 2010-06-11 EP EP10727515.8A patent/EP2440065B1/en active Active
- 2010-06-11 US US13/377,572 patent/US20120136053A1/en not_active Abandoned
- 2010-06-11 DK DK10727515.8T patent/DK2440065T3/en active
- 2010-06-11 JP JP2012514911A patent/JP2012529503A/ja active Pending
- 2010-06-11 RU RU2011153933/13A patent/RU2539921C2/ru active
- 2010-06-11 ES ES10727515T patent/ES2697533T3/es active Active
-
2013
- 2013-12-27 US US14/141,492 patent/US10485779B2/en active Active
-
2015
- 2015-10-15 JP JP2015203900A patent/JP6180485B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US10485779B2 (en) | 2019-11-26 |
RU2011153933A (ru) | 2013-07-20 |
CN102802428B (zh) | 2016-06-29 |
ES2697533T3 (es) | 2019-01-24 |
US20120136053A1 (en) | 2012-05-31 |
US20140105999A1 (en) | 2014-04-17 |
WO2010143977A1 (en) | 2010-12-16 |
CA2765329C (en) | 2018-01-02 |
EP2440065B1 (en) | 2018-09-26 |
JP2012529503A (ja) | 2012-11-22 |
CN102802428A (zh) | 2012-11-28 |
CA2765329A1 (en) | 2010-12-16 |
RU2539921C2 (ru) | 2015-01-27 |
EP2440065A1 (en) | 2012-04-18 |
DK2440065T3 (en) | 2018-12-10 |
JP2016074665A (ja) | 2016-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
La Lastra et al. | Mediterrranean diet and health biological importance of olive oil | |
US9610298B1 (en) | Omega-3 fatty acid nutriceutical composition and optimization method | |
TW200824582A (en) | Use of DPA(n-6) oils in infant formula | |
Matsuo et al. | Effects of structured medium-and long-chain triacylglycerols in diets with various levels of fat on body fat accumulation in rats | |
Chen et al. | Two filamentous microalgae as feed ingredients improved flesh quality and enhanced antioxidant capacity and immunity of the gibel carp (Carassius auratus gibelio) | |
JP6387371B2 (ja) | メタボリックシンドローム改善剤 | |
WO2010149662A1 (en) | Composition comprising omega-7 and/or omega-4 fatty acids | |
Liu et al. | Effect of dietary fatty acids on serum parameters, fatty acid compositions, and liver histology in Shaoxing laying ducks | |
Zaloga et al. | Lipid modulation and systemic inflammation | |
JP6180485B2 (ja) | オイル組成物、オイル組成物を含む製剤、及び内蔵脂肪の蓄積を減らし、ブドウ糖耐性を向上させて肥満関連疾患及び障害を予防又は治療するためのその使用 | |
JP2010105946A (ja) | 筋タンパク質増強剤及びこれを含む医薬品または食品 | |
Borghi et al. | Omega-3 polyunsaturated fatty acids: Their potential role in blood pressure prevention and management | |
Kaçar | n-3 and N-6 Fatty Acids in Fish: A Focus on Non-Marine Species | |
Pedersen | The new lipids from the Arctic | |
JP2020092691A (ja) | ケトン食用栄養組成物 | |
Stanek et al. | Fatty acids profile in Carassius spp. from lake Goplo, Poland | |
US11266665B1 (en) | Omega-3 fatty acid nutriceutical compositions and methods | |
WO2010117281A1 (en) | Feed composition and method of feeding gammaridae | |
Shrirang et al. | Functional Aspects of Foods Fortified With Omega-3 Fatty Acids | |
D’Angelo | Omega 3 fatty acids as nutraceuticals in sporting performances | |
Jalili et al. | Evaluation of Nutritional Quality of Caspian Shad Muscle, Alosa caspia caspia (Eichwald, 1838) in Southern Caspian Coast | |
JPWO2003074042A1 (ja) | 脱共役蛋白質発現亢進剤 | |
Merdzhanova et al. | Polyunsaturated fatty acids for the heart-powerful tools for prevention and therapy | |
Bederska-Łojewska et al. | REGULATION OF THE INTAKE OF ARACHIDONIC ACID BY MODIFYING ANIMAL PRODUCTS AND ITS EFFECT ON INFLAMMATORY PROCESSES IN THE HUMAN BODY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160809 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170106 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170404 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170628 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170711 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170718 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6180485 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |